A Study Evaluating a New Radiation Treatment Workflow (NGDS)

Study summary

The purpose of this research is to evaluate the "Next Generation Delivery System" (NGDS) and determine if this machine will be more efficient at delivering radiation in shorter treatment time and better patient tolerance, with less breath holding.

Ask AI to explain this study

Start here

Key things to know

Main goalDevice Feasibility

This describes the study’s primary purpose.

What is being studiedNext Generation Delivery System (NGDS)

The study team can explain what participation involves.

Who it may be forLung Cancer (Diagnosis) · Liver Cancer, Adult

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Sep 17, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Not applicable

Interventional

Where is it offered?2 U.S. locations

Locations may change over time.

Who runs it?Varian, a Siemens Healthineers Company

Study sponsor

Study overview

What this study is about

Purpose: Device Feasibility
Study type: Interventional
Phase: Not applicable
Sponsor: Varian, a Siemens Healthineers Company
Interventions being studied: Device: Next Generation Delivery System (NGDS)

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

1. Target lesions in the thorax or upper abdomen 2. Planned to undergo SBRT radiation treatment delivered on a conventional "C-arm" or ring gantry CBCT guided linear accelerator under breath hold conditions 3. ECOG performance status 0-1 4. At least 21 years of age 5. Able to sign informed consent

Reasons someone may not be able to joinExclusion criteria

1. Participants enrolled in another clinical investigation the investigator believes to be in conflict with this clinical investigation. 2. Participants with any other medical condition or laboratory value that would, at the discretion of the investigator, preclude the patient from participation in this clinical investigation.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Siteman Cancer Center Washington UniversitySt Louis, Missouri
University Hospital Cleveland Medical CenterCleveland, Ohio

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 17, 2026. Always confirm current availability with the study team.

View original record ↗